Glyscend is focused on the treatment of Type 2 Diabetes and Obesity through a novel class of gut-targeted polymer therapies, which aim to mimic the effects of bariatric surgery without invasive procedures. self-described.

Glyscend

Glyscend Therapeutics | 1,097 followers on LinkedIn. Advancing a new class of oral gut-targeted polymeric drugs for the treatment of T2D and Obesity | Developer of oral, gut-targeted polymer therapeutics for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety-advantages avoiding invasive complications of surgeries and procedures.

Biomaterials Innovator, Entrepreneur

Thomas H. Jozefiak

Co-Founder at Glyscend and LifeSprout

Kevin Colbert

CEO at Glyscend Therapeutics

Sapan Shah, PhD

Sajida Rahman

Glyscend Therapeutics

Did you know? Our lead clinical-stage candidate, GLY-200, takes a unique approach to treating type 2 #diabetes and #obesity . GLY-200 is an oral drug designed to enhance the natural mucus barrier in the upper small intestine to mimic the beneficial effects of metabolic surgery. This pharmacologic duodenal exclusion mechanism is aimed at providing more physiological and pleiotropic effects by modulating multiple gut-mediated metabolic signaling pathways. Learn more about GLY-200 at https://lnkd.in/g5UzY6dW Clinical progress highlights: ✅ GLY-200 treatment led to significant reductions in postprandial glucose and body weight in people with type 2 #diabetes with the most common side effects being mild gastrointestinal symptoms. ✅ Our ongoing 16-week Phase 2 #obesity trial of GLY-200 is fully enrolled, and we look forward to top-line results at year-end. #T2D #ClinicalResearch #NewTreatments

Glyscend is headed to ObesityWeek 2024 hosted by The Obesity Society in San Antonio, November 3-6! Our team will be presenting new data on GLY-200, an orally administered polymeric drug that targets gut mediated metabolic signaling, in a poster titled: “GLY-200 (Oral Duodenal Exclusion Drug) +/- Semaglutide Improves Metabolic Parameters in DIO Mice” (Poster‐220). The studies, done in collaboration with Randy Seeley at the University of Michigan , suggest that GLY-200 has mechanisms of action that are independent of (and complementary to) those of GLP1-RAs. GLY-200 is currently in Phase 2 clinical trials for the treatment of type 2 #diabetes and #obesity . Please stop by our poster to meet with the Glyscend team and hear more! At Glyscend Therapeutics, our mission is to advance novel oral medicines that can address the growing global obesity-diabetes epidemic. Learn more about us at www.glyscend.com . #OW2024 #t2d #weightloss #biotech #pharma

🎉We’re celebrating a milestone: Glyscend was founded 10 years ago this week! As we mark this momentous occasion, we send a heartfelt thank you to the employees, interns, investors, collaborators, and every individual who supported our mission of advancing novel oral therapies for #T2D and #obesity to improve patient outcomes and reduce costs across the healthcare system. We are proud of the journey we’ve taken to turn an idea into a Phase 2 clinical-stage drug candidate, and we look forward to many more exciting years of progress ahead. Special thanks: The Johns Hopkins University , Johns Hopkins Technology Ventures (JHTV) , Johns Hopkins Center for Bioengineering Innovation & Design , TEDCO , Maryland Department of Commerce , Maryland Tech Council , UMassM2D2 , JLABS @M2D2 , National Science Foundation (NSF) , Breakout Labs , SANTÉ , and Brandon Capital #T2DM #diabetes #clinicalresearch #pharma #biotech

Our Glyscend team had a great opportunity this month to get together for a group outing, touring the historic Pawtucket Canal off the Merrimack River in Lowell, MA. So wonderful to take a break and spend a beautiful summer day with colleagues!

The Glyscend team will be in Orlando for the American Diabetes Association 84th Scientific Sessions where we look forward to engaging with the #diabetes and #obesity community! Visit our 3 posters to see how our oral pharmacologic duodenal exclusion drug, GLY-200: ✅ Reduced glucose and bodyweight in patients with T2D (855-P, presented by Mark Fineman ) ✅ Decreased appetite, increased satiation, and reduced food intake in patients with T2D (864-P, presented by Christine Bryant ) ✅ Improved glycemic control as measured by CGM in patients with T2D (875-P, presented by Ashish Nimgaonkar, MD ) GLY-200 is an orally-administered, gut-targeted, polymeric drug in development for the treatment of type 2 diabetes and obesity. Learn more about us at Glyscend.com #ADA2024 #ADASciSessions #clinicalresearch #biopharma

Glyscend’s Chief Medical Officer, Ashish Nimgaonkar, MD , will be speaking at the 2nd Annual Obesity & Weight Loss Drug Development Summit this week. This meeting brings together industry leaders to discuss the development of more tolerable and sustainable next generation weight loss therapies. At Glyscend Therapeutics, our mission is to advance novel oral medicines that can address the growing global obesity-diabetes epidemic. Learn more about us at www.glyscend.com . #obesity #weightloss #biotech #biopharma

We are pleased to share that the first patient has been dosed in a 16-week Phase 2 #obesity trial of our lead candidate, GLY-200. This study follows our previously announced positive Phase 2 data with GLY-200 in patients with type 2 #diabetes . Based on its unique mechanism of oral pharmacologic duodenal exclusion, GLY-200 has the potential to provide meaningful weight-loss benefit and a well-tolerated profile to patients with obesity by activating multiple beneficial gut-mediated metabolic signaling pathways. GLY-200 was designed to mimic the beneficial effects of bariatric surgery with an oral drug and first dosing in this Phase 2 study of patients who are non-diabetic obese represents another significant milestone in our efforts to bring this first-in-class mechanism to patients. Read the full announcement here: https://lnkd.in/dw2SSGsz At Glyscend Therapeutics, our mission is to advance novel oral medicines that can address the growing global obesity-diabetes epidemic. Learn more about us at www.glyscend.com . Members of our leadership team will also be at #BIO2024 this week. Please reach out if you would like to connect. #weightloss #T2D #clinicalresearch #pharma #biotech

Glyscend is honored to have been nominated by the Maryland Tech Council as a 2024 ICON Award finalist for Emerging Life Sciences Company of the Year. We are proud to be recognized for our efforts to advance GLY-200 as a novel oral treatment for #obesity and type 2 #diabetes and are grateful to the investors, partners, and patients who have supported us. We look forward to attending the award ceremony in May and celebrating with all of the Finalists. Congratulations to all of the nominees who are doing such great work! Special thanks to: The Johns Hopkins University , Johns Hopkins Technology Ventures (JHTV) , Johns Hopkins Center for Bioengineering Innovation & Design , TEDCO , Maryland Department of Commerce , Maryland Tech Council, UMassM2D2 , JLABS@M2D2, National Science Foundation (NSF) , Breakout Labs , SANTÉ , and Brandon Capital https://lnkd.in/gVsXtG4s #t2d #biopharma #lifescience

Our CEO Sapan Shah, PhD will be on a panel discussing #MetabolicSyndrome at #JPM24 #BiotechShowcase next week. Join the panel moderated by Ruojing (Angus) Liu from Fierce Biotech next Wednesday, January 10th at 8 am PT. Panelists include: Sapan Shah, PhD , CEO, Glyscend Therapeutics Ashley Zehnder , CEO, Fauna Bio Alexander Fleming , CEO, Kinexum Services LLC Crystal Nyitray , CEO, Encellin Additional details here: https://lnkd.in/eZaESEs #pharma #biotech

From the entire Glyscend Team, wishing you and yours a joy-filled holiday season and New Year!

Metric
Company Name	Glyscend
Symbol
MSH ID	COM:GLYSCEND
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	glyscend.com
LinkedIn	glyscend-incorporated
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

GLYS

COM:GLYSCEND

Glyscend

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue